Patents Assigned to Vasopharm Biotech GmbH

Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species

Patent number: 8222238

Abstract: The present invention relates to the use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species.

Type: Grant

Filed: October 8, 2003

Date of Patent: July 17, 2012

Assignee: Vasopharm Biotech GmbH

Inventors: Robert Doblhofer, Frank Tegtmeier
Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species

Publication number: 20070032498

Abstract: The present invention relates to the use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species.

Type: Application

Filed: October 8, 2003

Publication date: February 8, 2007

Applicant: VASOPHARM BIOTECH GMBH

Inventors: Robert Doblhofer, Frank Tegtmeier
Isolated and purified human soluble guanylyl cyclase ?1/?1 (hsgc?1/?1)

Patent number: 6849438

Abstract: The invention relates to the expression of the cDNA clone for sub-units a1 (hsGCa1) and b1 (hsGCb1) of human soluble guanylylcyclase and the subsequent purification of the active enzyme and use thereof, the medical application of the expression of this clone by gene transfer, in addition to antibodies against peptides derived from said sequence and the use thereof.

Type: Grant

Filed: August 16, 1999

Date of Patent: February 1, 2005

Assignee: Vasopharm Biotech GmbH

Inventors: Harald Schmidt, Ulrike Zabel, Wolfgang Poller
N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent

Patent number: 6844343

Abstract: Compounds of formula (I), where preferably: A=a bridge of partial formula (II) or (III), R1 and R2=independently (substituted) alkyl, aryl or aralkyl, or together form a heterocycle, R3=H, —CO-Alkyl, or —CO-Aryl, R4=Aryl, —CO—O-Aryl or —CO-Aryl and R5=H, are potent inhibitors of NO-synthase and are suitable as pharmaceutical agents of prophylaxis and treatment of disease states associates with a disturbed NO metabolism.

Type: Grant

Filed: September 11, 2000

Date of Patent: January 18, 2005

Assignee: Vasopharm Biotech GmbH

Inventors: Wolfgang Pfleiderer, Harald Schmidt, Lothar Fröhlich, Peter Kotsonis, Shahriyar Taghavi-Moghadam
Antibodies against phosphorylated VASP ( vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use

Publication number: 20040063914

Abstract: The invention relates to antibodies against VASP (vasodilator-stimulated phosphoprotein) which only bind VASP as an antigen when VASP is present in phosphorylated form, to hybridoma cells for their preparation, and to the use of the antibodies or antibody fragments as diagnostic agents and/or therapeutic agents.

Type: Application

Filed: September 22, 2003

Publication date: April 1, 2004

Applicant: Vasopharm Biotech GmbH

Inventors: Martin Eigenthaler, Heinz Hoschuetzky, Ulrich Walter
Antibodies against phoshorylated VASP (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use

Patent number: 6649421

Abstract: The invention relates to antibodies against VASP (vasodilator-stimulated phosphoprotein) which only bind VASP as an antigen when VASP is present in phosphorylated form, to hybridoma cells for their preparation, and to the use of the antibodies or antibody fragments as diagnostic agents and/or therapeutic agents.

Type: Grant

Filed: June 21, 2000

Date of Patent: November 18, 2003

Assignee: Vasopharm Biotech GmbH

Inventors: Martin Eigenthaler, Heinz Hoschuetzky, Ulrich Walter

Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species

Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species

Isolated and purified human soluble guanylyl cyclase ?1/?1 (hsgc?1/?1)

N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent

Antibodies against phosphorylated VASP ( vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use

Antibodies against phoshorylated VASP (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use